Datapoint: GSK’s Latest Oncology Buy Includes Jakafi Competitor

GlaxoSmithKline last week unveiled plans to purchase Sierra Oncology for $1.9 billion. The highlight of the deal is momelotinib, Sierra’s promising JAK inhibitor. In a recent phase 3 clinical trial, momelotinib outperformed Incyte and Novartis’ Jakafi in controlling myelofibrosis, a rare blood cancer, and prevented anemia in patients. Sierra intends to file for FDA approval during the second quarter of 2022. For the treatment of myelofibrosis, virtually all insured lives have covered or better access to Jakafi. 17.5% of lives have preferred access to Jakafi without utilization management restrictions.

SOURCE: MMIT Analytics, as of 4/13/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 6

Datapoint: Moda Health to Expand to Idaho

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today